{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:34:26Z","timestamp":1787063666955,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100011033","name":"Ministry of Economy and Competitiveness | Agencia Estatal de Investigaci\u00f3n","doi-asserted-by":"publisher","award":["RYC-2017-23560"],"award-info":[{"award-number":["RYC-2017-23560"]}],"id":[{"id":"10.13039\/501100011033","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010067","name":"Gobierno de Arag\u00f3n","doi-asserted-by":"publisher","award":["E36-17R"],"award-info":[{"award-number":["E36-17R"]}],"id":[{"id":"10.13039\/501100010067","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003329","name":"Ministerio de Econom\u00eda y Competitividad","doi-asserted-by":"publisher","award":["FIS2017-87519-P"],"award-info":[{"award-number":["FIS2017-87519-P"]}],"id":[{"id":"10.13039\/501100003329","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In Tuberculosis (TB), given the complexity of its transmission dynamics, observations of reduced epidemiological risk associated with preventive interventions can be difficult to translate into mechanistic interpretations. Specifically, in clinical trials of vaccine efficacy, a readout of protection against TB disease can be mapped to multiple dynamical mechanisms, an issue that has been overlooked so far. Here, we describe this limitation and its effect on model-based evaluations of vaccine impact. Furthermore, we propose a methodology to analyze efficacy trials that circumvents it, leveraging a combination of compartmental models and stochastic simulations. Using our approach, we can disentangle the different possible mechanisms of action underlying vaccine protection effects against TB, conditioned to trial design, size, and duration. Our results unlock a deeper interpretation of the data emanating from efficacy trials of TB vaccines, which renders them more interpretable in terms of transmission models and translates into explicit recommendations for vaccine developers.<\/jats:p>","DOI":"10.1038\/s41467-019-13387-9","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T06:03:10Z","timestamp":1575007390000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccines"],"prefix":"10.1038","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0537-3650","authenticated-orcid":false,"given":"Mario","family":"Tovar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Arregui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dessislava","family":"Marinova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2993-5478","authenticated-orcid":false,"given":"Carlos","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yamir","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"key":"13387_CR1","unstructured":"WHO. Global Tuberculosis Report 2019 (World Health Organization, 2019)."},{"key":"13387_CR2","first-page":"21","volume":"3","author":"C Au-Yeung","year":"2011","unstructured":"Au-Yeung, C. et al. Tuberculosis mortality in HIV-infected individuals: a cross-national systematic assessment. Clin. Epidemiol. 3, 21\u201329 (2011).","journal-title":"Clin. Epidemiol."},{"key":"13387_CR3","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.3934\/dcds.2015.35.4639","volume":"35","author":"CJ Silva","year":"2015","unstructured":"Silva, C. J. & Torres, D. F. M. A TB-HIV\/AIDS coinfection model and optimal control treatment. Discret. Contin. Dyn. S 35, 4639\u20134663 (2015).","journal-title":"Discret. Contin. Dyn. S"},{"key":"13387_CR4","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1007\/s12038-008-0078-8","volume":"33","author":"A Jain","year":"2008","unstructured":"Jain, A. & Dixit, P. Multidrug resistant to extensively drug resistant tuberculosis: what is next? J. Biosciences 33, 605\u2013616 (2008).","journal-title":"J. Biosciences"},{"key":"13387_CR5","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.jtbi.2014.05.023","volume":"358","author":"JM Trauer","year":"2014","unstructured":"Trauer, J. M., Denholm, J. T. & McBryde, E. S. Construction of a mathematical model for tuberculosis transmission in highly endemic regions of the asia-pacific. J. Theor. Biol. 358, 74\u201384 (2014).","journal-title":"J. Theor. Biol."},{"key":"13387_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/nrdp.2016.76","volume":"2","author":"M Pai","year":"2016","unstructured":"Pai, M. et al. Tuberculosis. Nat. Rev. Dis. Primers. 2, 1\u201323 (2016).","journal-title":"Nat. Rev. Dis. Primers."},{"key":"13387_CR7","doi-asserted-by":"publisher","first-page":"319","DOI":"10.2174\/156652407780598520","volume":"7","author":"A Helen","year":"2007","unstructured":"Helen, A. Correlates of immune protection from tuberculosis. Curr. Mol. Med. 7, 319\u2013325 (2007).","journal-title":"Curr. Mol. Med."},{"key":"13387_CR8","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1128\/CVI.00721-14","volume":"22","author":"K Bhatt","year":"2015","unstructured":"Bhatt, K., Verma, S., Ellner, J. J. & Salgame, P. Quest for correlates of protection against tuberculosis. Clin. Vaccine Immunol. 22, 258\u2013266 (2015).","journal-title":"Clin. Vaccine Immunol."},{"key":"13387_CR9","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/S0140-6736(13)60177-4","volume":"381","author":"MD Tameris","year":"2013","unstructured":"Tameris, M. D. et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021\u20131028 (2013).","journal-title":"Lancet"},{"key":"13387_CR10","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1714021","volume":"379","author":"E Nemes","year":"2018","unstructured":"Nemes, E. et al. Prevention of M. tuberculosis infection with H4: IC31 vaccine or BCG revaccination. New Engl. J. Med. 379, 138\u2013149 (2018).","journal-title":"New Engl. J. Med."},{"key":"13387_CR11","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1803484","volume":"379","author":"O Van Der Meeren","year":"2018","unstructured":"Van Der Meeren, O. et al. Phase 2b controlled trial of M72\/AS01E vaccine to prevent tuberculosis. New Engl. J. Med. 379, 1621\u20131634 (2018).","journal-title":"New Engl. J. Med."},{"key":"13387_CR12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.12688\/f1000research.13588.1","volume":"7","author":"G Voss","year":"2018","unstructured":"Voss, G. et al. Progress and challenges in TB vaccine development. F1000Res 7, 199 (2018).","journal-title":"F1000Res"},{"key":"13387_CR13","doi-asserted-by":"publisher","first-page":"15520","DOI":"10.1073\/pnas.1404386111","volume":"111","author":"GM Knight","year":"2014","unstructured":"Knight, G. M. et al. Impact and cost-effectiveness of new tuberculosis vaccines in low-and middle-income countries. Proc. Natl Acad. Sci. USA 111, 15520\u201315525 (2014).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"13387_CR14","doi-asserted-by":"publisher","first-page":"k2738","DOI":"10.1136\/bmj.k2738","volume":"362","author":"MA Behr","year":"2018","unstructured":"Behr, M. A., Edelstein, P. H. & Ramakrishnan, L. Revisiting the timetable of tuberculosis. BMJ 362, k2738 (2018).","journal-title":"BMJ"},{"key":"13387_CR15","doi-asserted-by":"publisher","first-page":"13980","DOI":"10.1073\/pnas.0901720106","volume":"106","author":"LJ Abu-Raddad","year":"2009","unstructured":"Abu-Raddad, L. J. et al. Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106, 13980\u201313985 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"13387_CR16","doi-asserted-by":"publisher","first-page":"E3238","DOI":"10.1073\/pnas.1720606115","volume":"115","author":"S Arregui","year":"2018","unstructured":"Arregui, S. et al. Data-driven model for the assessment of Mycobacterium tuberculosis transmission in evolving demographic structures. Proc. Natl Acad. Sci. USA 115, E3238\u2013E3245 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"13387_CR17","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1016\/S1473-3099(18)30134-8","volume":"18","author":"NA Menzies","year":"2018","unstructured":"Menzies, N. A. et al. Progression from latent infection to active disease in dynamic tuberculosis transmission models: a systematic review of the validity of modelling assumptions. Lancet Infect. Dis. 18, e228\u2013e238 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"13387_CR18","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1146\/annurev-immunol-032712-095939","volume":"31","author":"O Anne","year":"2013","unstructured":"Anne, O. et al. The immune response in tuberculosis. Annu. Rev. Immunol. 31, 475\u2013527 (2013).","journal-title":"Annu. Rev. Immunol."},{"key":"13387_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1128\/CMR.00034-13","volume":"27","author":"M Pai","year":"2014","unstructured":"Pai, M. et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin. Microbiol. Rev. 27, 3\u201320 (2014).","journal-title":"Clin. Microbiol. Rev."},{"key":"13387_CR20","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1086\/338342","volume":"185","author":"T Lillebaek","year":"2002","unstructured":"Lillebaek, T. et al. Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J Infect Dis 185, 401\u20134 (2002).","journal-title":"J Infect Dis"},{"key":"13387_CR21","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1093\/cid\/cir951","volume":"54","author":"JR Andrews","year":"2012","unstructured":"Andrews, J. R. et al. Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54, 784\u2013791 (2012).","journal-title":"Clin. Infect. Dis."},{"key":"13387_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-017-0985-3","volume":"15","author":"ME Halloran","year":"2017","unstructured":"Halloran, M. E. et al. Simulations for designing and interpreting intervention trials in infectious diseases. BMC Med. 15, 223 (2017).","journal-title":"BMC Med."},{"key":"13387_CR23","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.4049\/jimmunol.1800993","volume":"201","author":"PL Lin","year":"2018","unstructured":"Lin, P. L. & Flynn, J. L. The end of the binary era: Revisiting the spectrum of tuberculosis. J. Immunol. 201, 2541\u20132548 (2018).","journal-title":"J. Immunol."},{"key":"13387_CR24","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1016\/S1473-3099(18)30421-3","volume":"18","author":"LK Schrager","year":"2018","unstructured":"Schrager, L. K. et al. WHO preferred product characteristics for new vaccines against tuberculosis. Lancet. Infect. Dis. 18, 828\u2013829 (2018).","journal-title":"Lancet. Infect. Dis."},{"key":"13387_CR25","doi-asserted-by":"publisher","first-page":"5067","DOI":"10.1016\/j.vaccine.2019.06.056","volume":"37","author":"S Abbott","year":"2019","unstructured":"Abbott, S. et al. Exploring the effects of BCG vaccination in patients diagnosed with tuberculosis: observational study using the Enhanced Tuberculosis Surveillance system. Vaccine 37, 5067\u20135072 (2019).","journal-title":"Vaccine"},{"key":"13387_CR26","first-page":"392","volume":"8","author":"BJ Marais","year":"2004","unstructured":"Marais, B. J. et al. The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era [State of the Art]. Int. J. Tuberc. Lung Dis. 8, 392\u2013402 (2004).","journal-title":"Int. J. Tuberc. Lung Dis."},{"key":"13387_CR27","unstructured":"David, D. Survival analysis in R. OpenIntro.org (2013)."},{"key":"13387_CR28","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1137\/S0036144500371907","volume":"42","author":"HW Hethcote","year":"2000","unstructured":"Hethcote, H. W. The mathematics of infectious diseases. SIAM Rev 42, 599\u2013653 (2000).","journal-title":"SIAM Rev"},{"key":"13387_CR29","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1016\/S0140-6736(98)03199-7","volume":"352","author":"C Dye","year":"1998","unstructured":"Dye, C., Garnett, G. P., Sleeman, K. & Williams, B. G. Prospects for worldwide tuberculosis control under the {WHO} {DOTS} strategy. Lancet 352, 1886\u20131891 (1998).","journal-title":"Lancet"},{"key":"13387_CR30","unstructured":"Bolker, B. et al. bbmle: Tools for general maximum likelihood estimation (2010)."},{"key":"13387_CR31","unstructured":"UN. Population division database. http:\/\/esa.un.org\/unpd\/wpp\/index.htm (2016)."},{"key":"13387_CR32","unstructured":"WHO. Tuberculosis database. http:\/\/www.who.int\/tb\/country\/en\/index.html (2016)."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13387-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13387-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T21:11:30Z","timestamp":1671225090000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-019-13387-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["13387"],"URL":"https:\/\/doi.org\/10.1038\/s41467-019-13387-9","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,29]]},"assertion":[{"value":"11 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.M. is a co-inventor on a composition of matter patent: Title: Tuberculosis Vaccine. Owner entity: Universidad de Zaragoza, Request number: PCT\/ES 2007\/070051. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5457"}}